Hormone patches are as good at controlling locally advanced prostate cancer as the injections typically used to deliver hormone therapy, according to the results of a large clinical trial led by UCL ...

A randomized phase III trial run out of the United Kingdom has found that estradiol skin patches suppress testosterone as effectively as standard hormone injections in men with locally advanced or ...

Camcevi ETM contains 21mg of leuprolide and is administered every 3 months. The Food and Drug Administration (FDA) has approved Camcevi ETM ®, a long-acting formulation of leuprolide mesylate, for the ...

Advanced prostate cancer is cancer that has spread beyond the prostate to distant parts of the body. It is also called metastatic or stage 4 prostate cancer. While most advanced prostate cancer is ...

Prostate cancer diagnoses increased by 3% per year from 2014 to 2021, with the sharpest increase seen in advanced-stage disease. Prostate cancer mortality rates have continued to decline, but at a ...

Researchers at Weill Cornell Medicine have led a phase 1 trial of a new drug that delivers potent radiation therapy directly and specifically to cancer cells in patients with advanced prostate cancer.

Experts project the diagnosis of over 300,000 prostate cancer cases in the United States in 2006, along with over 30,000 prostate cancer-related deaths. As such, prostate cancer remains the most ...

Doctors and scientists around the world are constantly searching for better ways to treat cancer. The goal is not only to help people live longer, but also to reduce side effects and improve quality ...

St Bartholomew's Hospital and The James Cook University Hospital mark key UK expansion of the company's Phase 2 mCRPC programme Dr Kenrick Ng, Medical Oncology Consultant, St Bartholomew's Hospital, ...